ClinicalTrials.gg
CompletedNCT00651664Updated Mar 15, 2019Results posted

A Phase I Clinical and Pharmacodynamic Study of MLN8237, A Novel Aurora A Kinase Inhibitor, in Participants With Advanced Malignancies

A Phase 1 interventional study of alisertib in Advanced Malignancies, sponsored by Millennium Pharmaceuticals, Inc.. Completed at 2 sites in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-03-15.

Sponsored by Millennium Pharmaceuticals, Inc. (part of Takeda) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 5 months after the study started (first participant enrolled Oct 2007, registered Mar 2008).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
59
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a multicenter, dose escalation, phase 1 study of MLN8237 in adult participants with advanced malignancies (excluding those with primary bone marrow involvement, such as leukemias and multiple myeloma).

Read the detailed description

The drug tested in this study is called alisertib. Alisertib is being tested to treat people who have advanced malignancies. This study determined the dose-limiting toxicity, maximum tolerated dose, safety and pharmacokinetics (how the drug moves through the body) for alisertib when given once or twice a day for 7 to 21 days.

This open label study enrolled 59 patients. Participants were enrolled in one of 10 dose escalation arms:

  • Alisertib 5 mg once daily (QD) for 7 Days (D)
  • Alisertib 80 mg QD 7D
  • Alisertib 150 mg QD 7D
  • Alisertib 50 mg twice daily (BID) 7D
  • Alisertib 60 mg BID 7D
  • Alisertib 75 mg BID 7D
  • Alisertib 100 mg BID 7D
  • Alisertib 50 mg QD 14D
  • Alisertib 50 mg QD 21D
  • Alisertib 70 mg QD 21D

All participants received treatment until their disease progressed or they experienced unacceptable alisertib-related toxicity.

This multi-center trial was conducted in Spain. The overall time to participate in this study was 730 days. Participants made multiple visits to the clinic, including a final visit 30 days after receiving their last dose of alisertib for a follow-up assessment.

02

Conditions studied

  • Advanced Malignancies
03

In context

Lead sponsor

Millennium Pharmaceuticals, Inc. is the lead sponsor of 178 studies on the registry; none are open to participants now.

Of its 74 completed or terminated interventional studies of FDA-regulated products, 73 (99%) have results posted.

First submitted before Millennium Pharmaceuticals, Inc. became part of Takeda.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Have a or cytologically confirmed and/or advanced (including lymphomas but excluding malignancies with extensive bone marrow involvement such as leukemias and multiple myeloma) for which standard treatment does not offer curative or life-prolonging potential.
  2. Aged 18 years or more.
  3. performance status 0 or 1.
  4. Have an expected survival longer than 3 months from enrollment in the study.
  5. Radiographically or clinically evaluable tumor.
  6. Suitable venous access for the conduct of blood sampling.
  7. Recovered from the reversible effects of prior antineoplastic therapy (with the exception of alopecia and grade 1 neuropathy) with at least 4 weeks elapsed since the last exposure to cytotoxic chemotherapy or to radiotherapy and at least 6 weeks elapsed since exposure to nitrosoureas or mitomycin C. Participants treated with fully human monoclonal antibodies must not have received treatment with such antibodies for at least 6 weeks, and those treated with chimeric monoclonal antibodies must not have received treatment with such antibodies for at least 4 weeks. Participants treated with noncytotoxic small molecule drugs (eg, tyrosine kinase inhibitors, such as Tarceva® [erlotinib], and hormonal agents, such as Femara® [letrozole]) must not have received treatment with these drugs for at least 2 weeks before the first dose of alisertib was given.
  8. Male participants must use an appropriate method of barrier and inform any sexual partners that they must also use a reliable method of contraception from the time of until 3 months after the last dose of study treatment.
  9. Female participants must be at least 1 year, OR surgically sterile, OR if of , agree to 2 effective methods of nonhormonal contraception, or agree to completely abstain from heterosexual intercourse.
  10. Able to give written consent.

Exclusion criteria

Exclusion Criteria:

  1. Pregnant or lactating.
  2. Major surgery or serious infection within the 28 days preceding the first dose of study treatment.
  3. Life-threatening or uncontrolled medical illness unrelated to cancer.
  4. Ongoing nausea or vomiting of any severity.
  5. >Grade 1 diarrhea. Participants who require ongoing therapy with an antimotility agent to control diarrhea to a Grade 1 or lower level are not allowed to participate in this trial.
  6. Known gastrointestinal disease or gastrointestinal procedures that could interfere with the oral absorption or tolerance of MLN8237.
  7. History of uncontrolled sleep apnea syndrome and other conditions that could result in excessive daytime sleepiness such as severe .
  8. Difficulty swallowing capsules.
  9. Inability to take nothing by mouth except for water and prescribed medications for 2 hours before and 1 hour after each dose of MLN8237.
  10. Received more than 4 previous cytotoxic chemotherapeutic regimens, including regimens used as or neo-adjuvant therapies (in participants with breast cancer, a total of 5 previous cytotoxic chemotherapeutic regimens is permitted).
  11. Prior treatment with high-dose chemotherapy, defined as chemotherapy requiring the use of peripheral blood or bone marrow stem cell support for hematopoietic reconstitution.
  12. Prior treatment with radiation therapy involving ≥25% of the hematopoietically active bone marrow for the distribution of active bone marrow in adults).
  13. Clinical and/or radiographic evidence of cerebral metastases. However, participants who have a history of central nervous system metastasis but who have no radiographic or clinical evidence of residual tumor (eg, following complete surgical resection or stereotactic radiosurgery) are not excluded from participation in this study.
  14. (ANC) \< 1500/mm\^3; count\< 100,000/mm\^3.
  15. Serum creatinine >1.6 mg/dL or a measured or estimated ( formula) creatinine clearance \<40 mL/min
  16. >1.5 times the (ULN); (AST)/alanine aminotransferase(ALT) >2.5 times the ULN, and alkaline phosphatase(ALP) >2.5 times the ULN. Both the AST and ALP could be elevated up to 5 times the ULN if their elevation could be reasonably ascribed to the presence of metastatic disease to liver and/or to bone; however, the ALT in all circumstances must have been \<2.5 times the ULN.
  17. Abnormalities on 12-lead considered by the investigator to be or baseline prolongation of the rate- interval (eg, repeated demonstration of QTc interval >450 milliseconds).
  18. Known history of (HIV) infection, or .
  19. Less than 4 weeks between the last dose of an agent and the first dose of MLN8237.
  20. Admission or evidence of benzodiazepine dependence or abuse and/or alcohol abuse or an inability to restrict consumption of alcohol to no more than 1 standard unit of alcohol per day during the study and for 30 days from the last dose of study treatment.
  21. (aPTT) and/or prothrombin time (PT) exceeding the upper limit of the normal range.
  22. Known bleeding diathesis or history of abnormal bleeding.
  23. Ongoing therapy with an anticoagulant (e.g., aspirin, plavix, coumadin).
Terms in these criteria, in plain language(24)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
59 participants (actual)

Study arms

  • Experimental
    Alisertib 5 mg QD 7D

    Alisertib 5 mg, capsules, orally, once daily (QD) for 7 days (D) followed by a 14-day recovery period in each cycle until disease progression or unacceptable alisertib-related toxicity (up to 3 cycles).

    Drug: alisertib

  • Experimental
    Alisertib 80 mg QD 7D

    Alisertib 80 mg, capsules, orally, QD for 7 days followed by a 14-day recovery period in each cycle until disease progression or unacceptable alisertib-related toxicity (up to 4 cycles).

    Drug: alisertib

  • Experimental
    Alisertib 150 mg QD 7D

    Alisertib 150 mg, capsules, orally, QD for 7 days followed by a 14-day recovery period in each cycle until disease progression or unacceptable alisertib-related toxicity (up to 6 cycles).

    Drug: alisertib

  • Experimental
    Alisertib 50 mg BID 7D

    Alisertib 50 mg, capsules, orally, twice daily (BID) for 7 days followed by a 14-day recovery period in each cycle until disease progression or unacceptable alisertib-related toxicity (up to 29 cycles).

    Drug: alisertib

  • Experimental
    Alisertib 60 mg BID 7D

    Alisertib 60 mg, capsules, orally, BID for 7 days followed by a 14-day recovery period in each cycle until disease progression or unacceptable alisertib-related toxicity (up to 6 cycles).

    Drug: alisertib

  • Experimental
    Alisertib 75 mg BID 7D

    Alisertib 75 mg, capsules, orally, BID for 7 days followed by a 14-day recovery period in each cycle until disease progression or unacceptable alisertib-related toxicity (up to 8 cycles).

    Drug: alisertib

  • Experimental
    Alisertib 100 mg BID 7D

    Alisertib 100 mg, capsules, orally, BID for 7 days followed by a 14-day recovery period in each cycle until disease progression or unacceptable alisertib-related toxicity (up to 21 cycles).

    Drug: alisertib

  • Experimental
    Alisertib 50 mg QD 14D

    Alisertib 50 mg, capsules, orally, QD for 14 days followed by a 14-day recovery period in each cycle until disease progression or unacceptable alisertib-related toxicity (up to 25 cycles).

    Drug: alisertib

  • Experimental
    Alisertib 50 mg QD 21D

    Alisertib 50 mg, capsules, orally, QD for 21 days followed by a 14-day recovery period in each cycle until disease progression or unacceptable alisertib-related toxicity (up to 10 cycles).

    Drug: alisertib

  • Experimental
    Alisertib 70 mg QD 21D

    Alisertib 70 mg, capsules, orally, QD for 21 days followed by a 14-day recovery period in each cycle until disease progression or unacceptable alisertib-related toxicity (up to 2 cycles).

    Drug: alisertib

Interventions

  • Alisertib (MLN8237) capsules

    Also known as: MLN8237

06

What researchers measure

Primary outcomes

  1. Number of Participants With Dose-Limiting Toxicity (DLT)

    DLT was evaluated using the National Cancer Institutes Common Terminology Criteria for Adverse Events (NCI CTCAE) version 3.0; defined as any of the following events related to alisertib therapy: 1. Grade 4 neutropenia lasting for ≥7 consecutive days during recovery 2. Grade 4 neutropenia with fever and/or infection 3. Confirmed platelet count \<25,000/mm\^3 4. ≥Grade 3 nausea and/or emesis despite the use of an antiemetic prophylaxis 5. ≥Grade 3 diarrhea that occurred despite therapy with loperamide 6. Any other Grade 3 or greater nonhematologic toxicity, with the following exceptions: Grade 3 arthralgia/myalgias, Any grade of alopecia, Brief (\< 1 week) Grade 3 fatigue 7. Treatment delay of \>1 week because of a failure of adequate hematologic or nonhematologic recovery from the previous cycle of treatment. 8. Other alisertib-related nonhematologic toxicities ≥ Grade 2 that, in the opinion of the investigator, required a dose reduction or discontinuation of therapy with alisertib.

    Time frame: First dose through 30 days following the last dose of study drug (up to 730 days)

  2. Maximum Tolerated Dose (MTD) of Alisertib

    The MTD was defined as the highest dose at which DLT occurred in 0/3 or 1/6 participants.

    Time frame: Signing of the Informed Consent through 30 days following the last dose of study drug (up to 730 days)

Secondary outcomes

  1. Cmax: Maximum Observed Concentration for Alisertib 7 Day Dosing

    Time frame: Cycle 1: Pre-dose and multiple time-points (up to 24 hour) post-dose on Day 1 and Pre-dose and multiple time-points (up to 10 hours) on Day 7

  2. Tmax: Time of First Occurrence of Cmax for Alisertib 7 Day Dosing

    Time frame: Cycle 1: Pre-dose and multiple time-points (up to 24 hour) post-dose on Day 1 and Pre-dose and multiple time-points (up to 10 hours) on Day 7

  3. AUCt: Area Under the Concentration-time Curve From Time 0 to Time t for Alisertib 7 Day Dosing

    Time frame: Cycle1: Pre-dose and multiple time-points (up to 24 hour) post-dose on Day 1 and Pre-dose and multiple time-points (up to 10 hours) on Day 7

  4. Terminal Half-Life (t1/2) for Alisertib 7 Day Dosing

    Time frame: Cycle 1: Pre-dose and multiple time-points (up to 10 hours) on Day 7 or 8 (BID arms)

  5. Accumulation Ratio (Rac) for Alisertib 7 Day Dosing

    Rac for Day 7=AUCt Day 7/AUCt Day 1.

    Time frame: Cycle 1: Pre-dose and multiple time-points (up to 10 hours) on Day 7

  6. Peak/Trough Ratio for Aliserib 7 Day Dosing

    Time frame: Cycle 1: Pre-dose and multiple time-points (up to 10 hours) on Day 7

  7. CLss/F: Apparent Oral Clearance at Steady State 7 Day Dosing

    Time frame: Cycle 1: Pre-dose and multiple time-points (up to 10 hours) on Day 7

  8. Cmax: Maximum Observed Concentration for Alisertib 14 Day Dosing

    Time frame: Cycle 1: Pre-dose and multiple time-points (up to 24 hour) post-dose on Day 1 and Pre-dose and multiple time-points (up to 10 hours) on Days 7 and 14

  9. Tmax: Time of First Occurrence of Cmax for Alisertib 14 Day Dosing

    Time frame: Cycle 1: Pre-dose and multiple time-points (up to 24 hour) post-dose on Day 1 and Pre-dose and multiple time-points (up to 10 hours) on Days 7 and 14

  10. AUCt: Area Under the Concentration-time Curve From Time 0 to Time t for Alisertib 14 Day Dosing

    Time frame: Cycle 1: Pre-dose and multiple time-points (up to 24 hour) post-dose on Day 1 and Pre-dose and multiple time-points (up to 10 hours) on Days 7 and 14

  11. Terminal Half-Life (t1/2) for Alisertib 14 Day Dosing

    Time frame: Cycle 1: Pre-dose and multiple time-points (up to 10 hours) on Days 7 and 14

  12. Accumulation Ratio (Rac) for Alisertib 14 Day Dosing

    Rac for Day 7=AUCt Day 7/AUCt Day 1. Rac for Day 14=AUCt Day 7/AUCt Day 1.

    Time frame: Cycle 1: Pre-dose and multiple time-points (up to 10 hours) on Days 7 and 14

  13. Peak/Trough Ratio for Aliserib 14 Day Dosing

    Time frame: Cycle 1: Pre-dose and multiple time-points (up to 10 hours) on Days 7 and 14

  14. CLss/F: Apparent Oral Clearance at Steady State 14 Day Dosing

    Time frame: Cycle 1: Pre-dose and multiple time-points (up to 10 hours) on Days 7 and 14

  15. Cmax: Maximum Observed Concentration for Alisertib 21 Day Dosing

    Time frame: Cycle 1: Pre-dose and multiple time-points (up to 24 hour) post-dose on Day 1 and Pre-dose and multiple time-points (up to 10 hours) on Days 14 and 21

  16. Tmax: Time of First Occurrence of Cmax for Alisertib 21 Day Dosing

    Time frame: Cycle 1: Pre-dose and multiple time-points (up to 24 hour) post-dose on Day 1 and Pre-dose and multiple time-points (up to 10 hours) on Days 14 and 21

  17. AUCt: Area Under the Concentration-time Curve From Time 0 to Time t for Alisertib 21 Day Dosing

    Time frame: Cycle 1: Pre-dose and multiple time-points (up to 24 hour) post-dose on Day 1 and Pre-dose and multiple time-points (up to 10 hours) on Days 14 and 21

  18. Terminal Half-Life (t1/2) for Alisertib 21 Day Dosing

    Time frame: Cycle 1: Pre-dose and multiple time-points (up to 10 hours) on Day 21

  19. Accumulation Ratio (Rac) for Alisertib 21 Day Dosing

    Rac for Day 7=AUCt Day 7/AUCt Day 1. Rac for Day 14=AUCt Day 7/AUCt Day 1. Rac for Day 21=AUCt Day 21/AUCt Day 1.

    Time frame: Cycle 1: Pre-dose and multiple time-points (up to 10 hours) on Days 14 and 21

  20. Peak/Trough Ratio for Aliserib 21 Day Dosing

    Time frame: Cycle 1: Pre-dose and multiple time-points (up to 10 hours) on Days 14 and 21

  21. CLss/F: Apparent Oral Clearance at Steady State 21 Day Dosing

    Time frame: Cycle 1: Pre-dose and multiple time-points (up to 10 hours) on Days 14 and 21

  22. Change From Baseline in Alisertib Skin Punch Biopsy Mitotic Index 7 Day Dosing

    Mitotic index was defined as the mean number of mitotic cells per millimeter (mm) length of the basoepithelial layer (BEL). Mitotic cells were counted manually within the BEL of 4, 5 micrometer (µm) skin sections stained with fluorescent-tagged antibodies specific to 2 mitotic markers; histone H3 phosphorylated on serine 10 (pHistH3) and MPM2. Deoxyribonucleic acid (DNA) was stained with a fluorescent marker as well. A positive change from Baseline indicates improvement.

    Time frame: Cycle 1: Pre-dose (Baseline) and Day 1, 6 hours post-dose; Day 7, 6 and 24 hours post-dose.

  23. Change From Baseline in Alisertib Skin Punch Biopsy Mitotic Index 14 Day Dosing

    Mitotic index was defined as the mean number of mitotic cells per millimeter (mm) length of the basoepithelial layer (BEL). Mitotic cells were counted manually within the BEL of 4, 5 micrometer (µm) skin sections stained with fluorescent-tagged antibodies specific to 2 mitotic markers; histone H3 phosphorylated on serine 10 (pHistH3) and MPM2. Deoxyribonucleic acid (DNA) was stained with a fluorescent marker as well. A positive change from Baseline indicates improvement.

    Time frame: Cycle 1: Pre-dose (Baseline) and Day 1 and 7, 6 hours post-dose; Day 14, 6 and 24 hours post-dose

  24. Change From Baseline in Alisertib Skin Punch Biopsy Mitotic Index 21 Day Dosing

    Mitotic index was defined as the mean number of mitotic cells per millimeter (mm) length of the basoepithelial layer (BEL). Mitotic cells were counted manually within the BEL of 4, 5 micrometer (µm) skin sections stained with fluorescent-tagged antibodies specific to 2 mitotic markers; histone H3 phosphorylated on serine 10 (pHistH3) and MPM2. Deoxyribonucleic acid (DNA) was stained with a fluorescent marker as well. A positive change from Baseline indicates improvement.

    Time frame: Cycle 1: Pre-dose (Baseline) and Day 7, 14 and 21, 6 hours post-dose

  25. Change From Baseline in Alisertib Skin Punch Biopsy Apoptotic Index 7 Day Dosing

    Apoptotic index was defined as the mean number of apoptotic cells per mm length of the basoepithelial layer (BEL). Apoptotic cells were counted manually within the BEL of 4, 5 µm skin sections stained with hematoxylin and eosin. A positive change from Baseline indicates improvement.

    Time frame: Cycle 1: Day 1, 6 hours post-dose; Days 7 6 and 24 hours post-dose; Day 21: 6 hours post-dose

  26. Change From Baseline in Alisertib Skin Punch Biopsy Apoptotic Index 14 Day Dosing

    Apoptotic index was defined as the mean number of apoptotic cells per mm length of the basoepithelial layer (BEL). Apoptotic cells were counted manually within the BEL of 4, 5 µm skin sections stained with hematoxylin and eosin. A positive change from Baseline indicates improvement.

    Time frame: Cycle 1: Pre-dose (Baseline) and Day 1, 6 hours post-dose; Days 7 and 14, 6 and 24 hours post-dose

  27. Change From Baseline in Alisertib Skin Punch Biopsy Apoptotic Index 21 Day Dosing

    Apoptotic index was defined as the mean number of apoptotic cells per mm length of the basoepithelial layer (BEL). Apoptotic cells were counted manually within the BEL of 4, 5 µm skin sections stained with hematoxylin and eosin. A positive change from Baseline indicates improvement.

    Time frame: Cycle 1: Pre-dose (Baseline) and Day 1, 6 hours post-dose; Days 7 and 14, 6 and 24 hours post-dose; Day 21: 6 hours post-dose

  28. Change From Baseline in Alisertib Tumor Biopsy Mitotic Index 7 Day Dosing

    Tumor biopsy sections were immunoflourescently labeled with proliferative marker Ki67 and mitotic marker pHistH3. DNA was stained with a fluorescent marker as well. The Mitotic index was determined from the percentage of pHistH3 immunopositive cells within the Ki67 positive area. A positive change from Baseline indicates improvement.

    Time frame: Cycle 1: Pre-dose (Baseline) and Days 1 and 7, 6 hours post-dose

  29. Change From Baseline in Alisertib Tumor Biopsy Mitotic Index 14 Day Dosing

    Tumor biopsy sections were immunoflourescently labeled with proliferative marker Ki67 and mitotic marker pHistH3. DNA was stained with a fluorescent marker as well. The Mitotic index was determined from the percentage of pHistH3 immunopositive cells within the Ki67 positive area. A positive change from Baseline indicates improvement.

    Time frame: Cycle 1: Pre-dose (Baseline) and Day 7, 6 hours post-dose

  30. Change From Baseline in Alisertib Tumor Biopsy Mitotic Index 21 Day Dosing

    Tumor biopsy sections were immunoflourescently labeled with proliferative marker Ki67 and mitotic marker pHistH3. DNA was stained with a fluorescent marker as well. The Mitotic index was determined from the percentage of pHistH3 immunopositive cells within the Ki67 positive area. A positive change from Baseline indicates improvement.

    Time frame: Cycle 1: Pre-dose (Baseline) and Days 7 and 21, 6 hours post-dose

Other outcomes

  1. Percentage of Participants With Polymorphisms in Gene Encoding Enzyme UGT1A1

    A blood sample was collected prior to alisertib dosing for the purpose of genotyping for polymorphisms in UGT1A1. The percentage of participants in the polymorphism categories: wt/wt, wt/\*28, \*28/\*28, \*28/wt, \*28/other and other/other is reported. wt=wild type. \*28 polymorphism in the promoter region of a UGT1A1 allele resulting in reduced UGT1A1 expression.

    Time frame: Cycle 1: Pre-dose

07

Results

Posted Mar 15, 2019

Participant flow

Participants took part in the study at 2 investigative sites in Spain from 22 October 2007 to 05 April 2011.

Participant flow — Overall Study
MilestoneAlisertib 5 mg QD 7DAlisertib 80 mg QD 7DAlisertib 150 mg QD 7DAlisertib 50 mg BID 7DAlisertib 60 mg BID 7DAlisertib 75 mg BID 7DAlisertib 100 mg BID 7DAlisertib 50 mg QD 14DAlisertib 50 mg QD 21DAlisertib 70 mg QD 21D
Started33314636777
Completed0000000000
Not completed33314636777
Withdrew: Occurrence of adverse event(s)0000001010
Withdrew: Unsatisfactory therapeutic response0000110101
Withdrew: Progressive disease33312413655
Withdrew: Patient declined further treatment0001110001
Withdrew: Symptomatic deterioration0001001010
Withdrew: Reason not specified0000001000

Outcome measures

PrimaryNumber of Participants With Dose-Limiting Toxicity (DLT)

DLT was evaluated using the National Cancer Institutes Common Terminology Criteria for Adverse Events (NCI CTCAE) version 3.0; defined as any of the following events related to alisertib therapy: 1. Grade 4 neutropenia lasting for ≥7 consecutive days during recovery 2. Grade 4 neutropenia with fever and/or infection 3. Confirmed platelet count \<25,000/mm\^3 4. ≥Grade 3 nausea and/or emesis despite the use of an antiemetic prophylaxis 5. ≥Grade 3 diarrhea that occurred despite therapy with loperamide 6. Any other Grade 3 or greater nonhematologic toxicity, with the following exceptions: Grade 3 arthralgia/myalgias, Any grade of alopecia, Brief (\< 1 week) Grade 3 fatigue 7. Treatment delay of \>1 week because of a failure of adequate hematologic or nonhematologic recovery from the previous cycle of treatment. 8. Other alisertib-related nonhematologic toxicities ≥ Grade 2 that, in the opinion of the investigator, required a dose reduction or discontinuation of therapy with alisertib.

Time frame:
First dose through 30 days following the last dose of study drug (up to 730 days)
Reported as:
Number · participants
Number of Participants With Dose-Limiting Toxicity (DLT)
participantsAlisertib 5 mg QD 7DAlisertib 80 mg QD 7DAlisertib 150 mg QD 7DAlisertib 50 mg BID 7DAlisertib 60 mg BID 7DAlisertib 75 mg BID 7DAlisertib 100 mg BID 7DAlisertib 50 mg QD 14DAlisertib 50 mg QD 21DAlisertib 70 mg QD 21D
Number of Participants With Dose-Limiting Toxicity (DLT)0000223113
PrimaryMaximum Tolerated Dose (MTD) of Alisertib

The MTD was defined as the highest dose at which DLT occurred in 0/3 or 1/6 participants.

Time frame:
Signing of the Informed Consent through 30 days following the last dose of study drug (up to 730 days)
Reported as:
Number · mg BID for 7 Days
Maximum Tolerated Dose (MTD) of Alisertib
mg BID for 7 DaysAlisertib
Maximum Tolerated Dose (MTD) of Alisertib50
SecondaryCmax: Maximum Observed Concentration for Alisertib 7 Day Dosing
Time frame:
Cycle 1: Pre-dose and multiple time-points (up to 24 hour) post-dose on Day 1 and Pre-dose and multiple time-points (up to 10 hours) on Day 7
Reported as:
Geometric mean · nanomolar (nM)
Cmax: Maximum Observed Concentration for Alisertib 7 Day Dosing
nanomolar (nM)Alisertib 5 mg QD 7DAlisertib 80 mg QD 7DAlisertib 150 mg QD 7DAlisertib 50 mg BID 7DAlisertib 60 mg BID 7DAlisertib 75 mg BID 7DAlisertib 100 mg BID 7D
Day 1123.15 ± 6.5541774.12 ± 36.4962014.81 ± 22.0381035.3 ± 75.701536.1 ± 44.701266.6 ± 45.693196.4 ± 51.11
Day 7109.13 ± 34.4581502.89 ± 32.8184136.24 ± 26.2531964.4 ± 46.263412.5 ± 27.065710.4 ± 23.894694.2 ± 38.86
SecondaryTmax: Time of First Occurrence of Cmax for Alisertib 7 Day Dosing
Time frame:
Cycle 1: Pre-dose and multiple time-points (up to 24 hour) post-dose on Day 1 and Pre-dose and multiple time-points (up to 10 hours) on Day 7
Reported as:
Median · hour(hr)
Tmax: Time of First Occurrence of Cmax for Alisertib 7 Day Dosing
hour(hr)Alisertib 5 mg QD 7DAlisertib 80 mg QD 7DAlisertib 150 mg QD 7DAlisertib 50 mg BID 7DAlisertib 60 mg BID 7DAlisertib 75 mg BID 7DAlisertib 100 mg BID 7D
Day 11.920 (1.58 to 2.00)2.730 (1.70 to 4.00)4.000 (2.00 to 5.90)2.040 (2.00 to 6.17)2.000 (2.00 to 4.08)2.000 (2.00 to 2.10)3.835 (1.98 to 4.08)
Day 71.670 (1.00 to 1.97)1.580 (1.50 to 6.00)1.550 (1.42 to 3.43)2.000 (1.25 to 8.00)2.000 (0.92 to 4.00)4.170 (1.75 to 5.83)1.580 (1.00 to 6.00)
SecondaryAUCt: Area Under the Concentration-time Curve From Time 0 to Time t for Alisertib 7 Day Dosing
Time frame:
Cycle1: Pre-dose and multiple time-points (up to 24 hour) post-dose on Day 1 and Pre-dose and multiple time-points (up to 10 hours) on Day 7
Reported as:
Geometric mean · nM*hour(h)
AUCt: Area Under the Concentration-time Curve From Time 0 to Time t for Alisertib 7 Day Dosing
nM*hour(h)Alisertib 5 mg QD 7DAlisertib 80 mg QD 7DAlisertib 150 mg QD 7DAlisertib 50 mg BID 7DAlisertib 60 mg BID 7DAlisertib 75 mg BID 7DAlisertib 100 mg BID 7D
Day 1975.0 ± NA18204.2 ± 36.1927262.7 ± 38.06314.1 ± 82.329771.5 ± 53.776895.3 ± 9.2116541.5 ± 65.99
Day 7658.5 ± 35.6416101.6 ± 38.8148421.8 ± 36.5317795.6 ± 43.8725853.3 ± 41.4451684.4 ± 24.8740166.7 ± 51.90
SecondaryTerminal Half-Life (t1/2) for Alisertib 7 Day Dosing
Time frame:
Cycle 1: Pre-dose and multiple time-points (up to 10 hours) on Day 7 or 8 (BID arms)
Reported as:
Mean · hr
Terminal Half-Life (t1/2) for Alisertib 7 Day Dosing
hrAlisertib 5 mg QD 7DAlisertib 80 mg QD 7DAlisertib 150 mg QD 7DAlisertib 50 mg BID 7DAlisertib 60 mg BID 7DAlisertib 75 mg BID 7DAlisertib 100 mg BID 7D
Terminal Half-Life (t1/2) for Alisertib 7 Day Dosing—18.25 ± 8.69719.80 ± 6.12915.913 ± 6.476619.475 ± 15.501918.500 ± 7.629513.637 ± 6.8712
SecondaryAccumulation Ratio (Rac) for Alisertib 7 Day Dosing

Rac for Day 7=AUCt Day 7/AUCt Day 1.

Time frame:
Cycle 1: Pre-dose and multiple time-points (up to 10 hours) on Day 7
Reported as:
Mean · ratio
Accumulation Ratio (Rac) for Alisertib 7 Day Dosing
ratioAlisertib 5 mg QD 7DAlisertib 80 mg QD 7DAlisertib 150 mg QD 7DAlisertib 50 mg BID 7DAlisertib 60 mg BID 7DAlisertib 75 mg BID 7DAlisertib 100 mg BID 7D
Accumulation Ratio (Rac) for Alisertib 7 Day Dosing0.874 ± 00.892 ± 0.13311.954 ± 0.90922.295 ± 0.98462.583 ± 0.89597.765 ± 1.91632.350 ± 1.4926
SecondaryPeak/Trough Ratio for Aliserib 7 Day Dosing
Time frame:
Cycle 1: Pre-dose and multiple time-points (up to 10 hours) on Day 7
Reported as:
Mean · ratio
Peak/Trough Ratio for Aliserib 7 Day Dosing
ratioAlisertib 5 mg QD 7DAlisertib 80 mg QD 7DAlisertib 150 mg QD 7DAlisertib 50 mg BID 7DAlisertib 60 mg BID 7DAlisertib 75 mg BID 7DAlisertib 100 mg BID 7D
Peak/Trough Ratio for Aliserib 7 Day Dosing5.950 ± 0.32534.650 ± 0.21634.507 ± 0.30293.083 ± 2.22963.050 ± 1.40561.867 ± 0.60092.256 ± 1.2013
SecondaryCLss/F: Apparent Oral Clearance at Steady State 7 Day Dosing
Time frame:
Cycle 1: Pre-dose and multiple time-points (up to 10 hours) on Day 7
Reported as:
Geometric mean · liter(L)/hr
CLss/F: Apparent Oral Clearance at Steady State 7 Day Dosing
liter(L)/hrAlisertib 5 mg QD 7DAlisertib 80 mg QD 7DAlisertib 150 mg QD 7DAlisertib 50 mg BID 7DAlisertib 60 mg BID 7DAlisertib 75 mg BID 7DAlisertib 100 mg BID 7D
CLss/F: Apparent Oral Clearance at Steady State 7 Day Dosing14.055 ± 27.69959.604 ± 35.51105.967 ± 31.25925.414 ± 57.92214.182 ± 51.27612.795 ± 23.57944.798 ± 49.4182
SecondaryCmax: Maximum Observed Concentration for Alisertib 14 Day Dosing
Time frame:
Cycle 1: Pre-dose and multiple time-points (up to 24 hour) post-dose on Day 1 and Pre-dose and multiple time-points (up to 10 hours) on Days 7 and 14
Reported as:
Geometric mean · nM
Cmax: Maximum Observed Concentration for Alisertib 14 Day Dosing
nMAlisertib 50 mg QD 14D
Day 11145.4 ± 53.09
Day 71418.1 ± 70.96
Day 141671.1 ± 51.66
SecondaryTmax: Time of First Occurrence of Cmax for Alisertib 14 Day Dosing
Time frame:
Cycle 1: Pre-dose and multiple time-points (up to 24 hour) post-dose on Day 1 and Pre-dose and multiple time-points (up to 10 hours) on Days 7 and 14
Reported as:
Median · hr
Tmax: Time of First Occurrence of Cmax for Alisertib 14 Day Dosing
hrAlisertib 50 mg QD 14D
Day 12.030 (1.00 to 6.00)
Day 72.000 (2.00 to 4.00)
Day 142.000 (1.02 to 4.00)
SecondaryAUCt: Area Under the Concentration-time Curve From Time 0 to Time t for Alisertib 14 Day Dosing
Time frame:
Cycle 1: Pre-dose and multiple time-points (up to 24 hour) post-dose on Day 1 and Pre-dose and multiple time-points (up to 10 hours) on Days 7 and 14
Reported as:
Geometric mean · nM*hr
AUCt: Area Under the Concentration-time Curve From Time 0 to Time t for Alisertib 14 Day Dosing
nM*hrAlisertib 50 mg QD 14D
Day 115363.0 ± 24.82
Day 717918.8 ± 78.55
Day 1416449.8 ± 59.87
SecondaryTerminal Half-Life (t1/2) for Alisertib 14 Day Dosing
Time frame:
Cycle 1: Pre-dose and multiple time-points (up to 10 hours) on Days 7 and 14
Reported as:
Mean · hr
Terminal Half-Life (t1/2) for Alisertib 14 Day Dosing
hrAlisertib 50 mg QD 14D
Terminal Half-Life (t1/2) for Alisertib 14 Day Dosing26.62 ± 13.611
SecondaryAccumulation Ratio (Rac) for Alisertib 14 Day Dosing

Rac for Day 7=AUCt Day 7/AUCt Day 1. Rac for Day 14=AUCt Day 7/AUCt Day 1.

Time frame:
Cycle 1: Pre-dose and multiple time-points (up to 10 hours) on Days 7 and 14
Reported as:
Mean · ratio
Accumulation Ratio (Rac) for Alisertib 14 Day Dosing
ratioAlisertib 50 mg QD 14D
Day 71.671 ± 0.8242
Day 141.813 ± 0.5001
SecondaryPeak/Trough Ratio for Aliserib 14 Day Dosing
Time frame:
Cycle 1: Pre-dose and multiple time-points (up to 10 hours) on Days 7 and 14
Reported as:
Mean · ratio
Peak/Trough Ratio for Aliserib 14 Day Dosing
ratioAlisertib 50 mg QD 14D
Day 74.415 ± 2.5016
Day 147.412 ± 4.2472
SecondaryCLss/F: Apparent Oral Clearance at Steady State 14 Day Dosing
Time frame:
Cycle 1: Pre-dose and multiple time-points (up to 10 hours) on Days 7 and 14
Reported as:
Geometric mean · L/hr
CLss/F: Apparent Oral Clearance at Steady State 14 Day Dosing
L/hrAlisertib 50 mg QD 14D
Day 75.381 ± 92.8272
Day 145.856 ± 98.2758
SecondaryCmax: Maximum Observed Concentration for Alisertib 21 Day Dosing
Time frame:
Cycle 1: Pre-dose and multiple time-points (up to 24 hour) post-dose on Day 1 and Pre-dose and multiple time-points (up to 10 hours) on Days 14 and 21
Reported as:
Geometric mean · nM
Cmax: Maximum Observed Concentration for Alisertib 21 Day Dosing
nMAlisertib 50 mg QD 21DAlisertib 70 mg QD 21D
Day 11112.3 ± 42.992220.3 ± 47.57
Day 141524.1 ± 64.252595.0 ± 42.98
Day 211651.7 ± 30.702093.7 ± 11.68
SecondaryTmax: Time of First Occurrence of Cmax for Alisertib 21 Day Dosing
Time frame:
Cycle 1: Pre-dose and multiple time-points (up to 24 hour) post-dose on Day 1 and Pre-dose and multiple time-points (up to 10 hours) on Days 14 and 21
Reported as:
Median · hr
Tmax: Time of First Occurrence of Cmax for Alisertib 21 Day Dosing
hrAlisertib 50 mg QD 21DAlisertib 70 mg QD 21D
Day 14.000 (2.00 to 6.17)2.000 (2.00 to 2.02)
Day 142.070 (1.00 to 4.00)2.130 (2.00 to 5.08)
Day 212.100 (2.00 to 24.80)2.125 (2.00 to 2.33)
SecondaryAUCt: Area Under the Concentration-time Curve From Time 0 to Time t for Alisertib 21 Day Dosing
Time frame:
Cycle 1: Pre-dose and multiple time-points (up to 24 hour) post-dose on Day 1 and Pre-dose and multiple time-points (up to 10 hours) on Days 14 and 21
Reported as:
Geometric mean · nM*hr
AUCt: Area Under the Concentration-time Curve From Time 0 to Time t for Alisertib 21 Day Dosing
nM*hrAlisertib 50 mg QD 21DAlisertib 70 mg QD 21D
Day 111701.0 ± 49.7818953.4 ± 56.89
Day 1420262.8 ± 71.3430918.3 ± 55.68
Day 2118264.9 ± 28.6724515.6 ± 23.80
SecondaryTerminal Half-Life (t1/2) for Alisertib 21 Day Dosing
Time frame:
Cycle 1: Pre-dose and multiple time-points (up to 10 hours) on Day 21
Reported as:
Mean · hr
Terminal Half-Life (t1/2) for Alisertib 21 Day Dosing
hrAlisertib 50 mg QD 21DAlisertib 70 mg QD 21D
Terminal Half-Life (t1/2) for Alisertib 21 Day Dosing20.13 ± 6.32626.13 ± 9.780
SecondaryAccumulation Ratio (Rac) for Alisertib 21 Day Dosing

Rac for Day 7=AUCt Day 7/AUCt Day 1. Rac for Day 14=AUCt Day 7/AUCt Day 1. Rac for Day 21=AUCt Day 21/AUCt Day 1.

Time frame:
Cycle 1: Pre-dose and multiple time-points (up to 10 hours) on Days 14 and 21
Reported as:
Mean · ratio
Accumulation Ratio (Rac) for Alisertib 21 Day Dosing
ratioAlisertib 50 mg QD 21DAlisertib 70 mg QD 21D
Day 142.482 ± 2.71662.103 ± 0.3861
Day 211.678 ± 0.75871.933 ± 1.1104
SecondaryPeak/Trough Ratio for Aliserib 21 Day Dosing
Time frame:
Cycle 1: Pre-dose and multiple time-points (up to 10 hours) on Days 14 and 21
Reported as:
Mean · ratio
Peak/Trough Ratio for Aliserib 21 Day Dosing
ratioAlisertib 50 mg QD 21DAlisertib 70 mg QD 21D
Day 144.070 ± 2.47513.628 ± 0.4864
Day 214.792 ± 2.56524.658 ± 2.1825
SecondaryCLss/F: Apparent Oral Clearance at Steady State 21 Day Dosing
Time frame:
Cycle 1: Pre-dose and multiple time-points (up to 10 hours) on Days 14 and 21
Reported as:
Geometric mean · L/hr
CLss/F: Apparent Oral Clearance at Steady State 21 Day Dosing
L/hrAlisertib 50 mg QD 21DAlisertib 70 mg QD 21D
Day 144.753 ± 70.56364.364 ± 47.3164
Day 215.276 ± 28.13565.593 ± 21.8384
SecondaryChange From Baseline in Alisertib Skin Punch Biopsy Mitotic Index 7 Day Dosing

Mitotic index was defined as the mean number of mitotic cells per millimeter (mm) length of the basoepithelial layer (BEL). Mitotic cells were counted manually within the BEL of 4, 5 micrometer (µm) skin sections stained with fluorescent-tagged antibodies specific to 2 mitotic markers; histone H3 phosphorylated on serine 10 (pHistH3) and MPM2. Deoxyribonucleic acid (DNA) was stained with a fluorescent marker as well. A positive change from Baseline indicates improvement.

Time frame:
Cycle 1: Pre-dose (Baseline) and Day 1, 6 hours post-dose; Day 7, 6 and 24 hours post-dose.
Reported as:
Mean · cells/mm
Change From Baseline in Alisertib Skin Punch Biopsy Mitotic Index 7 Day Dosing
cells/mmAlisertib 5 mg QD 7DAlisertib 80 mg QD 7DAlisertib 150 mg QD 7DAlisertib 50 mg BID 7DAlisertib 60 mg BID 7DAlisertib 75 mg BID 7DAlisertib 100 mg BID 7D
Day 1, 6 Hours Post-Dose0.187 ± 0.07090.107 ± 0.07770.197 ± 0.08140.310 ± 0.20870.378 ± 0.41070.175 ± 0.23330.850 ± 1.0741
Day 7, 6 Hours Post-Dose0.193 ± 0.16500.617 ± 0.75142.703 ± 0.71123.489 ± 2.68936.220 ± 5.75498.757 ± 4.04939.150 ± 8.9050
Day 7, 24 Hours Post-Dose0.140 ± 0.11790.397 ± 0.21595.270 ± 3.83253.184 ± 4.49841.250 ± 0.000025.190 ± 1.767817.123 ± 9.4877
SecondaryChange From Baseline in Alisertib Skin Punch Biopsy Mitotic Index 14 Day Dosing

Mitotic index was defined as the mean number of mitotic cells per millimeter (mm) length of the basoepithelial layer (BEL). Mitotic cells were counted manually within the BEL of 4, 5 micrometer (µm) skin sections stained with fluorescent-tagged antibodies specific to 2 mitotic markers; histone H3 phosphorylated on serine 10 (pHistH3) and MPM2. Deoxyribonucleic acid (DNA) was stained with a fluorescent marker as well. A positive change from Baseline indicates improvement.

Time frame:
Cycle 1: Pre-dose (Baseline) and Day 1 and 7, 6 hours post-dose; Day 14, 6 and 24 hours post-dose
Reported as:
Mean · cells/mm
Change From Baseline in Alisertib Skin Punch Biopsy Mitotic Index 14 Day Dosing
cells/mmAlisertib 50 mg QD 14D
Day 1, 6 Hours Post-Dose1.180 ± 0.0000
Day 7, 6 Hours Post-Dose0.950 ± 0.9963
Day 14, 6 Hours Post-Dose1.146 ± 1.6239
Day 7, 24 Hours Post-Dose0.368 ± 0.4464
SecondaryChange From Baseline in Alisertib Skin Punch Biopsy Mitotic Index 21 Day Dosing

Mitotic index was defined as the mean number of mitotic cells per millimeter (mm) length of the basoepithelial layer (BEL). Mitotic cells were counted manually within the BEL of 4, 5 micrometer (µm) skin sections stained with fluorescent-tagged antibodies specific to 2 mitotic markers; histone H3 phosphorylated on serine 10 (pHistH3) and MPM2. Deoxyribonucleic acid (DNA) was stained with a fluorescent marker as well. A positive change from Baseline indicates improvement.

Time frame:
Cycle 1: Pre-dose (Baseline) and Day 7, 14 and 21, 6 hours post-dose
Reported as:
Mean · cells/mm
Change From Baseline in Alisertib Skin Punch Biopsy Mitotic Index 21 Day Dosing
cells/mmAlisertib 50 mg QD 21DAlisertib 70 mg QD 21D
Day 7, 6 Hours Post-Dose1.534 ± 1.92011.900 ± 2.2774
Day 14, 6 Hours Post-Dose0.341 ± 0.31821.168 ± 0.7587
Day 21, 6 Hours Post-Dose0.250 ± 1.4530.565 ± 0.5565
SecondaryChange From Baseline in Alisertib Skin Punch Biopsy Apoptotic Index 7 Day Dosing

Apoptotic index was defined as the mean number of apoptotic cells per mm length of the basoepithelial layer (BEL). Apoptotic cells were counted manually within the BEL of 4, 5 µm skin sections stained with hematoxylin and eosin. A positive change from Baseline indicates improvement.

Time frame:
Cycle 1: Day 1, 6 hours post-dose; Days 7 6 and 24 hours post-dose; Day 21: 6 hours post-dose
Reported as:
Mean · cells/mm
Change From Baseline in Alisertib Skin Punch Biopsy Apoptotic Index 7 Day Dosing
cells/mmAlisertib 5 mg QD 7DAlisertib 80 mg QD 7DAlisertib 150 mg QD 7DAlisertib 50 mg BID 7DAlisertib 60 mg BID 7DAlisertib 75 mg BID 7DAlisertib 100 mg BID 7D
Day 1, 6 hour post-dose0.080 ± 0.06930.000 ± 0.00000.097 ± 0.08500.040 ± 0.06340.000 ± 0.00000.055 ± 0.07780.242 ± 0.2566
Day 7, 6 hour post-dose0.040 ± 0.06930.560 ± 0.96991.303 ± 0.59501.525 ± 2.23993.173 ± 4.31706.040 ± 1.99285.162 ± 2.2801
Day 7, 24 hour post-dose0.040 ± 0.06930.343 ± 0.49442.145 ± 1.64761.050 ± 1.7490.830 ± 0.007.715 ± 0.12024.713 ± 1.1924
SecondaryChange From Baseline in Alisertib Skin Punch Biopsy Apoptotic Index 14 Day Dosing

Apoptotic index was defined as the mean number of apoptotic cells per mm length of the basoepithelial layer (BEL). Apoptotic cells were counted manually within the BEL of 4, 5 µm skin sections stained with hematoxylin and eosin. A positive change from Baseline indicates improvement.

Time frame:
Cycle 1: Pre-dose (Baseline) and Day 1, 6 hours post-dose; Days 7 and 14, 6 and 24 hours post-dose
Reported as:
Mean · cells/mm
Change From Baseline in Alisertib Skin Punch Biopsy Apoptotic Index 14 Day Dosing
cells/mmAlisertib 50 mg QD 14D
Day 1, 6 hours post-dose0.000 ± 0.000
Day 7, 6 hours post-dose0.390 ± 0.8721
Day 14, 6 hours post-dose0.484 ± 0.7869
Day 14, 24 hours post-dose0.260 ± 0.3834
SecondaryChange From Baseline in Alisertib Skin Punch Biopsy Apoptotic Index 21 Day Dosing

Apoptotic index was defined as the mean number of apoptotic cells per mm length of the basoepithelial layer (BEL). Apoptotic cells were counted manually within the BEL of 4, 5 µm skin sections stained with hematoxylin and eosin. A positive change from Baseline indicates improvement.

Time frame:
Cycle 1: Pre-dose (Baseline) and Day 1, 6 hours post-dose; Days 7 and 14, 6 and 24 hours post-dose; Day 21: 6 hours post-dose
Reported as:
Mean · cells/mm
Change From Baseline in Alisertib Skin Punch Biopsy Apoptotic Index 21 Day Dosing
cells/mmAlisertib 50 mg QD 21DAlisertib 70 mg QD 21D
Day 7, 6 hours post-dose0.606 ± 0.99540.379 ± 0.6276
Day 14, 6 hours post-dose0.146 ± 0.23550.404 ± 0.4334
Day 21, 6 hours post-dose0.134 ± 0.16980.230 ± 0.1283
SecondaryChange From Baseline in Alisertib Tumor Biopsy Mitotic Index 7 Day Dosing

Tumor biopsy sections were immunoflourescently labeled with proliferative marker Ki67 and mitotic marker pHistH3. DNA was stained with a fluorescent marker as well. The Mitotic index was determined from the percentage of pHistH3 immunopositive cells within the Ki67 positive area. A positive change from Baseline indicates improvement.

Time frame:
Cycle 1: Pre-dose (Baseline) and Days 1 and 7, 6 hours post-dose
Reported as:
Mean · percentage of cells
Change From Baseline in Alisertib Tumor Biopsy Mitotic Index 7 Day Dosing
percentage of cellsAlisertib 5 mg QD 7DAlisertib 80 mg QD 7DAlisertib 150 mg QD 7DAlisertib 50 mg BID 7DAlisertib 60 mg BID 7DAlisertib 75 mg BID 7DAlisertib 100 mg BID 7D
Day 1, 6 hours post-dose0.125 ± 0.10610.610 ± 0.00006.460 ± 9.10751.464 ± 1.32941.080 ± 0.33940.090 ± 0.00002.907 ± 2.0284
Day 7, 6 hours post-dose1.145 ± 0.03540.590 ± 0.000015.500 ± 13.56232.020 ± 2.95673.115 ± 3.16085.840 ± 0.00003.527 ± 2.1258
SecondaryChange From Baseline in Alisertib Tumor Biopsy Mitotic Index 14 Day Dosing

Tumor biopsy sections were immunoflourescently labeled with proliferative marker Ki67 and mitotic marker pHistH3. DNA was stained with a fluorescent marker as well. The Mitotic index was determined from the percentage of pHistH3 immunopositive cells within the Ki67 positive area. A positive change from Baseline indicates improvement.

Time frame:
Cycle 1: Pre-dose (Baseline) and Day 7, 6 hours post-dose
Reported as:
Mean · percentage of cells
Change From Baseline in Alisertib Tumor Biopsy Mitotic Index 14 Day Dosing
percentage of cellsAlisertib 50 mg QD 14D
Change From Baseline in Alisertib Tumor Biopsy Mitotic Index 14 Day Dosing0.008 ± 0.0000
SecondaryChange From Baseline in Alisertib Tumor Biopsy Mitotic Index 21 Day Dosing

Tumor biopsy sections were immunoflourescently labeled with proliferative marker Ki67 and mitotic marker pHistH3. DNA was stained with a fluorescent marker as well. The Mitotic index was determined from the percentage of pHistH3 immunopositive cells within the Ki67 positive area. A positive change from Baseline indicates improvement.

Time frame:
Cycle 1: Pre-dose (Baseline) and Days 7 and 21, 6 hours post-dose
Reported as:
Mean · percentage of cells
Change From Baseline in Alisertib Tumor Biopsy Mitotic Index 21 Day Dosing
percentage of cellsAlisertib 50 mg QD 21DAlisertib 70 mg QD 21D
Day 7, 6 hours post-dose0.027 ± 0.01710.050 ± 0.0243
Day 21, 6 hours post-dose0.014 ± 0.00720.054 ± 0.0038
Other pre-specifiedPercentage of Participants With Polymorphisms in Gene Encoding Enzyme UGT1A1

A blood sample was collected prior to alisertib dosing for the purpose of genotyping for polymorphisms in UGT1A1. The percentage of participants in the polymorphism categories: wt/wt, wt/\*28, \*28/\*28, \*28/wt, \*28/other and other/other is reported. wt=wild type. \*28 polymorphism in the promoter region of a UGT1A1 allele resulting in reduced UGT1A1 expression.

Time frame:
Cycle 1: Pre-dose
Reported as:
Number · percentage of participants
Percentage of Participants With Polymorphisms in Gene Encoding Enzyme UGT1A1
percentage of participantsAlisertib
wt/wt34
wt/*2844
*28/*287
*28/wt0
*28/other0
other/other2

Adverse events

Collected over Signing of the Informed Consent through 30 days following the last dose of study drug (up to 730 days). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Alisertib 5 mg QD 7D—1/3 (33.3%)3/39 (7.7%)
Alisertib 80 mg QD 7D—1/3 (33.3%)3/30 (10%)
Alisertib 150 mg QD 7D—1/3 (33.3%)3/101 (3%)
Alisertib 50 mg BID 7D—6/14 (42.9%)14/142 (9.9%)
Alisertib 60 mg BID 7D—3/6 (50%)6/68 (8.8%)
Alisertib 75 mg BID 7D—1/3 (33.3%)3/68 (4.4%)
Alisertib 100 mg BID 7D—5/6 (83.3%)6/194 (3.1%)
Alisertib 50 mg QD 14D—1/7 (14.3%)7/119 (5.9%)
Alisertib 50 mg QD 21D—3/7 (42.9%)7/67 (10.4%)
Alisertib 70 mg QD 21D—4/7 (57.1%)7/68 (10.3%)
Most frequent serious events
Showing 10 of 25
Most frequent serious events
EventAlisertib 5 mg QD 7DAlisertib 80 mg QD 7DAlisertib 150 mg QD 7DAlisertib 50 mg BID 7DAlisertib 60 mg BID 7DAlisertib 75 mg BID 7DAlisertib 100 mg BID 7DAlisertib 50 mg QD 14DAlisertib 50 mg QD 21DAlisertib 70 mg QD 21D
StomatitisGastrointestinal disorders0/30/30/31/140/60/33/60/70/70/7
DiarrhoeaGastrointestinal disorders0/30/30/31/141/60/32/60/70/71/7
NeutropeniaBlood and lymphatic system disorders0/30/30/31/141/60/32/60/70/70/7
LymphadenopathyBlood and lymphatic system disorders0/30/30/30/140/61/30/60/70/70/7
Spinal cord compressionNervous system disorders0/31/30/30/140/60/30/60/70/70/7
Incorrect dose administeredInjury, poisoning and procedural complications0/30/31/30/140/60/30/60/70/70/7
Renal failureRenal and urinary disorders1/30/30/30/140/60/30/61/70/70/7
Lower gastrointestinal haemorrhageGastrointestinal disorders0/30/30/30/140/60/31/60/70/70/7
VomitingGastrointestinal disorders0/30/30/30/140/60/31/60/70/70/7
Febrile neutropeniaBlood and lymphatic system disorders0/30/30/30/140/60/31/60/70/70/7
Most frequent other events
Showing 10 of 144
Most frequent other events
EventAlisertib 5 mg QD 7DAlisertib 80 mg QD 7DAlisertib 150 mg QD 7DAlisertib 50 mg BID 7DAlisertib 60 mg BID 7DAlisertib 75 mg BID 7DAlisertib 100 mg BID 7DAlisertib 50 mg QD 14DAlisertib 50 mg QD 21DAlisertib 70 mg QD 21D
AnaemiaBlood and lymphatic system disorders2/32/32/38/144/63/35/65/74/71/7
LeukopeniaBlood and lymphatic system disorders0/31/32/38/143/62/36/62/71/74/7
NeutropeniaBlood and lymphatic system disorders0/31/33/34/144/62/33/62/73/72/7
AstheniaGeneral disorders3/30/32/33/143/62/35/63/76/74/7
AlopeciaSkin and subcutaneous tissue disorders0/32/33/31/144/62/34/61/73/75/7
LymphopeniaBlood and lymphatic system disorders0/30/32/39/142/61/30/66/72/70/7
ThrombocytopeniaBlood and lymphatic system disorders0/31/32/35/142/61/35/62/70/71/7
PyrexiaGeneral disorders0/30/31/31/141/61/35/64/71/72/7
NauseaGastrointestinal disorders1/30/32/31/142/61/34/62/73/75/7
SomnolenceNervous system disorders1/32/32/34/142/61/33/60/71/75/7

Baseline characteristics

Safety population was defined as all participants who received any amount of study drug.

Age, Continuous
Age, Continuous(years)Alisertib 5 mg QD 7DAlisertib 80 mg QD 7DAlisertib 150 mg QD 7DAlisertib 50 mg BID 7DAlisertib 60 mg BID 7DAlisertib 75 mg BID 7DAlisertib 100 mg BID 7DAlisertib 50 mg QD 14DAlisertib 50 mg QD 21DAlisertib 70 mg QD 21DTotal
Mean52.7 ± 9.0762.3 ± 13.8055.7 ± 20.7962.5 ± 11.6759.2 ± 18.7448.3 ± 14.8458.7 ± 8.6958.0 ± 13.8353.0 ± 11.0864.7 ± 5.5358.8 ± 12.46
Sex: Female, Male
Sex: Female, Male(Participants)Alisertib 5 mg QD 7DAlisertib 80 mg QD 7DAlisertib 150 mg QD 7DAlisertib 50 mg BID 7DAlisertib 60 mg BID 7DAlisertib 75 mg BID 7DAlisertib 100 mg BID 7DAlisertib 50 mg QD 14DAlisertib 50 mg QD 21DAlisertib 70 mg QD 21DTotal
Female012640223222
Male321823454537
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Alisertib 5 mg QD 7DAlisertib 80 mg QD 7DAlisertib 150 mg QD 7DAlisertib 50 mg BID 7DAlisertib 60 mg BID 7DAlisertib 75 mg BID 7DAlisertib 100 mg BID 7DAlisertib 50 mg QD 14DAlisertib 50 mg QD 21DAlisertib 70 mg QD 21DTotal
Hispanic/Latino3331463676556
Not Hispanic/Latino00000000123
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Alisertib 5 mg QD 7DAlisertib 80 mg QD 7DAlisertib 150 mg QD 7DAlisertib 50 mg BID 7DAlisertib 60 mg BID 7DAlisertib 75 mg BID 7DAlisertib 100 mg BID 7DAlisertib 50 mg QD 14DAlisertib 50 mg QD 21DAlisertib 70 mg QD 21DTotal
Number3331463677759
Region of Enrollment
Region of Enrollment(participants)Alisertib 5 mg QD 7DAlisertib 80 mg QD 7DAlisertib 150 mg QD 7DAlisertib 50 mg BID 7DAlisertib 60 mg BID 7DAlisertib 75 mg BID 7DAlisertib 100 mg BID 7DAlisertib 50 mg QD 14DAlisertib 50 mg QD 21DAlisertib 70 mg QD 21DTotal
Spain3331463677759
Height
Height(cm)Alisertib 5 mg QD 7DAlisertib 80 mg QD 7DAlisertib 150 mg QD 7DAlisertib 50 mg BID 7DAlisertib 60 mg BID 7DAlisertib 75 mg BID 7DAlisertib 100 mg BID 7DAlisertib 50 mg QD 14DAlisertib 50 mg QD 21DAlisertib 70 mg QD 21DTotal
Mean164.0 ± 7.21164.3 ± 10.79167.3 ± 1.53165.8 ± 9.26160.5 ± 4.76171.3 ± 10.26165.2 ± 10.21169.9 ± 10.92160.4 ± 11.57167.6 ± 8.40165.4 ± 9.15
Weight
Weight(kg)Alisertib 5 mg QD 7DAlisertib 80 mg QD 7DAlisertib 150 mg QD 7DAlisertib 50 mg BID 7DAlisertib 60 mg BID 7DAlisertib 75 mg BID 7DAlisertib 100 mg BID 7DAlisertib 50 mg QD 14DAlisertib 50 mg QD 21DAlisertib 70 mg QD 21DTotal
Mean83.7 ± 32.1375.2 ± 10.5670.3 ± 4.2474.4 ± 16.4864.8 ± 6.8390.5 ± 7.7469.6 ± 16.2276.7 ± 15.0669.1 ± 14.7877.9 ± 11.9174.0 ± 14.95
Body Surface Area (BSA)
Body Surface Area (BSA)(m^2)Alisertib 5 mg QD 7DAlisertib 80 mg QD 7DAlisertib 150 mg QD 7DAlisertib 50 mg BID 7DAlisertib 60 mg BID 7DAlisertib 75 mg BID 7DAlisertib 100 mg BID 7DAlisertib 50 mg QD 14DAlisertib 50 mg QD 21DAlisertib 70 mg QD 21DTotal
Mean1.93 ± 0.3931.85 ± 0.1911.81 ± 0.0471.85 ± 0.2251.70 ± 0.1022.07 ± 0.0981.78 ± 0.2441.87 ± 0.2041.75 ± 0.2311.90 ± 0.1451.84 ± 0.208
08

Study locations

2 sites
  • Ciutat Sanitaria Vall d'Hebron - Servicio de Oncologia
    Barcelona, 08035, Spain
  • H. Clínico Universitario de Valencia
    Valencia, Spain
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2007 to primary completion in Sep 2010, 34 months.

Results were first posted in Mar 2019, 8 years 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 31, 2008
First posted
Apr 3, 2008
StartActual
Oct 22, 2007
Primary completionActual
Sep 1, 2010
CompletionActual
Apr 5, 2011
Results first posted
Mar 15, 2019
Last update
Mar 15, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 15, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00651664
Responsible party
Sponsor
First posted
Apr 3, 2008
Start date
Oct 22, 2007
Primary completion
Sep 1, 2010
Completion
Apr 5, 2011
Results posted
Mar 15, 2019
Last update
Mar 15, 2019

Study contacts

Medical Director Clinical Science
study director · Takeda

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: MLN 8237

Start the discussion